We visited Charlotte, North Carolina for a State of the Science Summit on Genitourinary Cancers. The meeting covered practice-changing clinical trials in nonmetastatic castration-resistant prostate cancer, treatment options for those with castration-sensitive prostate cancer, and the role of surgery in high-risk prostate cancer. Additionally, immunotherapy in advanced renal cell carcinoma was discussed, along with the optimal sequencing of tyrosine kinase inhibitors, and the need for a traditional RCC treatment approach.